These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32760020)

  • 1. Federal judge invalidates icosapent ethyl patents - but on the basis of a common statistical mistake.
    Curfman G; Bhatt DL; Pencina M
    Nat Biotechnol; 2020 Aug; 38(8):939-941. PubMed ID: 32760020
    [No Abstract]   [Full Text] [Related]  

  • 2. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amarin files patent infringement suit on lipid-lowering drug.
    Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):350. PubMed ID: 26900610
    [No Abstract]   [Full Text] [Related]  

  • 4. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
    Bays HE; Ballantyne CM; Doyle RT; Juliano RA; Philip S
    Prostaglandins Other Lipid Mediat; 2016 Sep; 125():57-64. PubMed ID: 27418543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icosapent ethyl for treatment of elevated triglyceride levels.
    Nelson SD; Munger MA
    Ann Pharmacother; 2013 Nov; 47(11):1517-23. PubMed ID: 24259598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Braeckman RA; Philip S; Stirtan WG; Doyle RT; Soni PN; Juliano RA
    J Clin Lipidol; 2016; 10(3):635-645.e1. PubMed ID: 27206952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
    Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.
    Braeckman RA; Stirtan WG; Soni PN
    Clin Drug Investig; 2015 Jan; 35(1):45-51. PubMed ID: 25471740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
    Reddy KJ; Chowdhury S
    Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
    Mosca L; Ballantyne CM; Bays HE; Guyton JR; Philip S; Doyle RT; Juliano RA
    Am J Cardiol; 2017 Feb; 119(3):397-403. PubMed ID: 27939227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.
    Jia X; Koh S; Al Rifai M; Blumenthal RS; Virani SS
    Vasc Health Risk Manag; 2020; 16():1-10. PubMed ID: 32021223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
    Kim ES; McCormack PL
    Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
    Crandell JR; Tartaglia C; Tartaglia J
    Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of cardiovascular risk with icosapent ethyl (Vascepa).
    Med Lett Drugs Ther; 2020 Feb; 62(1591):17-18. PubMed ID: 32022786
    [No Abstract]   [Full Text] [Related]  

  • 19. Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial.
    Miller M
    Future Cardiol; 2019 Nov; 15(6):391-394. PubMed ID: 31524535
    [No Abstract]   [Full Text] [Related]  

  • 20. Translating plasma eicosapentaenoic acid concentrations into erythrocyte percentages of eicosapentaenoic acid plus docosahexaenoic acid during treatment with icosapent ethyl.
    Harris WS; Jackson KH
    J Clin Lipidol; 2019; 13(5):771-777. PubMed ID: 31401072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.